V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210036898 | 210012844 | null | 47 | Curative (C) | 2014-01-17 | 2018-08-15 | Cytarabine intrathecal | N | null | 210037617 | CYTARABINE HD + METHOTREXATE HD |
| 210036899 | 210038650 | 0 | 61.7 | Curative (C) | 2015-10-22 | 2015-10-31 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | 02 | null | 210037781 | CAPECITABINE |
| 210036900 | 210012882 | 1.72 | null | Palliative (P) | null | 2017-08-20 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | N | N | 210037785 | IRINOTECAN + MDG |
| 210036901 | 210012890 | null | 68.6 | Curative (C) | 2018-06-08 | 2018-06-14 | Phase 2 Induction (ALL) | Y | null | 210037803 | PACKER MAINTENANCE |
| 210036902 | 210022152 | 1.65 | 54 | Curative (C) | 2015-05-28 | 2018-10-02 | Cytarabine intrathecal | N | N | 210038157 | TAMIGA TRIAL |
| 210036903 | 210022154 | 1.21 | 50 | null | 2015-07-19 | 2015-07-19 | BEAM | 99 | N | 210038174 | TAMIGA TRIAL |
| 210036904 | 210022157 | 0 | 66.7 | Palliative (P) | null | 2020-02-01 | CNS LGG Irinotecan & Bevacizumab | N | null | 210038187 | DOXORUBICIN |
| 210036905 | 210012985 | 1.52 | null | Curative (C) | 2012-07-17 | 2016-12-12 | Cytarabine intrathecal | N | N | 210038312 | CISPLATIN + ETOPOSIDE |
| 210036906 | 210027920 | null | 76.7 | Disease modification (D) | 2017-06-19 | 2017-06-19 | Cytarabine intrathecal | Y | N | 210038363 | OFATUMUMAB |
| 210036907 | 210013026 | 1.79 | null | Curative (C) | 2018-07-26 | 2018-07-26 | CVP | 01 | N | 210038500 | TAMIGA TRIAL |
| 210036908 | 210013068 | 1.72 | 68 | Curative (C) | 2017-11-30 | 2018-05-19 | TAMIGA trial | N | N | 210038669 | OLAPARIB |
| 210036909 | 210013109 | 1.63 | 74.2 | Palliative (P) | 2018-10-19 | 2018-10-20 | PEMBROLIZUMAB | N | N | 210038851 | BEVACIZUMAB + LOMUSTINE |
| 210036910 | 210013145 | 0 | null | Curative (C) | 2020-01-15 | 2020-01-15 | TAMIGA trial | N | N | 210039036 | DOCETAXEL |
| 210036911 | 210027977 | 1.65 | 76.399 | Curative (C) | 2015-03-16 | 2015-03-16 | CYCLET | N | N | 210039212 | PACKER MAINTENANCE |
| 210036912 | 210013212 | null | 69.8 | Disease modification (D) | 2016-02-19 | 2016-02-19 | CAV | 2 | N | 210039328 | BR14 TRIAL |
| 210036913 | 210022306 | 1.55 | 68.8 | Curative (C) | 2016-07-17 | 2016-07-21 | Fludarabine IV | null | null | 210039434 | FEC |
| 210036914 | 210013260 | 1.67 | 54 | Palliative (P) | null | 2016-07-30 | CISPLATIN + VINCRISTINE | Y | N | 210039601 | ERIBULIN |
| 210036915 | 210013271 | 1.72 | 108.4 | Curative (C) | 2019-03-05 | 2019-04-09 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | N | N | 210039685 | ERLOTINIB |
| 210036916 | 210013287 | 0 | 0 | Palliative (P) | 2015-05-12 | 2015-05-13 | CYTARABINE | N | N | 210039746 | NILOTINIB |
| 210036917 | 210013316 | null | 68.6 | Curative (C) | null | 2017-04-01 | FLAG | N | null | 210039899 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210036918 | 210031493 | null | 91.2 | Curative (C) | 2017-12-17 | 2017-12-18 | CNS LGG Irinotecan & Bevacizumab | 02 | null | 210040628 | PENTOSTATIN + RITUXIMAB |
| 210036919 | 210013483 | 0 | 54.4 | Curative (C) | 2018-07-16 | 2018-07-16 | CLOFARABINE + CYCLO + CYTARABINE + ETOP | 2 | N | 210040958 | VAI |
| 210036920 | 210013493 | 1.62 | 56.3 | Curative (C) | 2015-04-06 | 2015-08-11 | Depocyte Intrathecal | Y | N | 210041021 | BRENTUXIMAB |
| 210036921 | 210028093 | null | 12.2 | null | 2016-01-29 | 2016-11-17 | BCG Intravesical | 2 | null | 210041357 | VINORELBINE |
| 210036922 | 210013623 | 1.74 | 75.8 | Palliative (P) | 2020-04-28 | 2020-04-28 | CNS Medbl Std Risk Maint Cisplatin | 02 | N | 210041817 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210036923 | 210022531 | 0 | 98 | Palliative (P) | 2018-06-18 | 2018-06-18 | BR14 TRIAL | null | null | 210042069 | CLARITY TRIAL |
| 210036924 | 210013674 | null | 11.8 | Curative (C) | null | 2018-12-05 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | null | 210000284 | ALL |
| 210036925 | 210028184 | 1.65 | 68.6 | Curative (C) | 2011-09-26 | 2018-06-03 | CARBOPLATIN + LOMUSTINE + VINCRISTINE | N | N | 210028705 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210036926 | 210035167 | 1.82 | 76 | Curative (C) | null | 2016-07-23 | FCR IV - Cycle 2 onwards | N | N | 210029666 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210036927 | 210013814 | 1.72 | null | Curative (C) | 2019-07-05 | 2019-07-19 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | Y | null | 210030225 | ICE-R |
| 210036928 | 210013842 | 1.56 | 93 | Curative (C) | 2017-03-12 | 2017-11-20 | Bevacizumab + Temozolomide | N | null | 210031205 | BORTEZOMIB |
| 210036929 | 210013883 | 1.79 | null | Curative (C) | 2016-12-27 | 2017-12-26 | MITOMYCIN | N | N | 210033322 | IDARUBICIN |
| 210036930 | 210013931 | 0 | 74.7 | null | null | 2018-11-12 | THALIDOMIDE | N | N | 210035201 | FLUDARABINE |
| 210036931 | 210013953 | 1.85 | 68.2 | Curative (C) | 2018-09-29 | 2018-10-10 | Cytarabine intrathecal | Y | N | 210036454 | OXALIPLATIN + MDG |
| 210036932 | 210014051 | 1.67 | null | Disease modification (D) | null | 2019-09-29 | ABVD | N | N | 210041781 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210036933 | 210022771 | 1.81 | 55.6 | Disease modification (D) | 2019-04-16 | 2019-04-20 | Abiraterone | N | N | 210034307 | ALL MAINTENANCE |
| 210036935 | 210004377 | 1.84 | 85 | Adjuvant (A) | 2018-10-15 | 2018-10-23 | Temozolomide 200mg/m2 | 2 | N | 210000395 | TEMOZOLOMIDE |
| 210036936 | 210004406 | 1.71 | 59.8 | Palliative (P) | 2016-10-07 | 2017-01-14 | Temozolomide 200mg/m2 | N | N | 210000602 | TEMOZOLOMIDE |
| 210036937 | 210038311 | 1.71 | 132 | Palliative (P) | 2017-03-18 | 2017-03-18 | TEMOZOLOMIDE | 02 | null | 210000612 | TEMOZOLOMIDE |
| 210036938 | 210032436 | 1.69 | null | Adjuvant (A) | 2017-03-28 | 2017-03-28 | TEMOZOLOMIDE | N | N | 210000818 | TEMOZOLOMIDE |
| 210036939 | 210004511 | 1.83 | null | Curative (C) | 2019-10-12 | 2020-01-19 | Temozolomide 150mg/m2 | N | N | 210001305 | TEMOZOLOMIDE |
| 210036940 | 210004531 | 1.75 | null | Adjuvant (A) | 2014-06-26 | 2014-11-05 | Temozolomide 200mg/m2 | 2 | null | 210001469 | TEMOZOLOMIDE |
| 210036941 | 210017348 | 1.78 | 88.4 | Adjuvant (A) | 2016-11-13 | 2016-11-20 | Temozolomide 200mg/m2 | N | N | 210001686 | TEMOZOLOMIDE |
| 210036944 | 210017381 | 1.66 | 63 | Not known (9) | 2014-04-08 | 2014-07-09 | Temozolomide 200mg/m2 | N | N | 210002085 | TEMOZOLOMIDE |
| 210036945 | 210029539 | 0 | 64.5 | Curative (C) | 2019-09-03 | 2019-09-07 | TEMOZOLOMIDE | 02 | null | 210002644 | TEMOZOLOMIDE |
| 210036946 | 210004761 | 1.82 | 66.65 | Curative (C) | null | 2015-07-24 | TEMOZOLOMIDE | null | null | 210002776 | TEMOZOLOMIDE |
| 210036947 | 210004798 | 1.72 | 76.5 | null | 2012-07-05 | 2015-01-19 | Temozolomide 200mg/m2 | N | N | 210002975 | TEMOZOLOMIDE |
| 210036948 | 210017477 | 0 | 49 | Curative (C) | 2017-05-04 | 2018-04-11 | ALL UKALL2011 Maintenance A1 | Y | N | 210003399 | UKALL2011 |
| 210036949 | 210017493 | null | 14.45 | Curative (C) | 2018-08-02 | 2018-08-23 | ALL UKALL2011 Std BFM Cons B | Y | null | 210003544 | UKALL2011 |
| 210036950 | 210004895 | 0.96 | 21.2 | Curative (C) | 2015-07-25 | 2015-08-07 | ALL UKALL2011 Maintenance A1 | 01 | null | 210003552 | UKALL2011 |